News | September 10, 2025
Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The facility has been designed with a dual focus on efficiency and sustainability
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
The company has received approval from DCGI to begin patient enrolment and dosing in the country
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Subscribe To Our Newsletter & Stay Updated
